VON Eschenbach Andrew C.
SEC-identified person · CIK 1536529 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Bausch & Lomb Corp BLCO | Director | filed 2022–2026 |
| Trisalus Life Sciences, Inc. TLSI | Director | filed 2023–2024 |
| GX Acquisition Corp. GXGXU | Director | filed 2021–2023 |
| Radius Health, Inc. RDUS | Director | filed 2021–2022 |
| Valeant Pharmaceuticals International, Inc. vrx | Director | filed 2018–2021 |
| Asterias Biotherapeutics, Inc. ASTY | Director | filed 2013–2014 |
| Lineage Cell Therapeutics, Inc. LCTX | Director | filed 2011–2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.